1921
Volume 85, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Because 8-aminoquinolines affect critical survival stages of parasites, treatment and control of malaria could be markedly improved by more widespread use of these drugs; however, hemolytic toxicity, which is widely prevalent in G6PD-deficient patients, severely constrains this use. Primaquine was approved more than 50 years ago after extensive clinical testing. Review of the mid-20th century literature in the light of present understanding of pharmacokinetics and metabolism suggests that manipulation of these factors might dissociate 8-aminoquinoline efficacy from toxicity and lead to an improved therapeutic index.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2011.11-0498
2011-12-01
2019-09-15
Loading full text...

Full text loading...

/deliver/fulltext/14761645/85/6/1010.html?itemId=/content/journals/10.4269/ajtmh.2011.11-0498&mimeType=html&fmt=ahah

References

  1. Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, Purnomo, Leksana B, Masbar S, Richie TL, Jones TR, Tjitra E, Wignall ES, Hoffman SL, , 1995. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 52: 479484. [Google Scholar]
  2. World Health Organization, 2006. Guidelines for the Treatment of Malaria, 2nd ed. Geneva, Switzerland: World Health Organization, 5258. [Google Scholar]
  3. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ, , 2010. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10: 673681.[Crossref] [Google Scholar]
  4. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN, , 2011. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612620.[Crossref] [Google Scholar]
  5. Beutler E, Duparc S, , 2007. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 77: 779789. [Google Scholar]
  6. WHO Working Group, 1989. G6PD deficiency. Bull World Health Organ 67: 601611. [Google Scholar]
  7. Brueckner RP, Ohrt C, Baird JK, Milhous W, Rosenthal PJ, , 2001. 8-aminoquinolines. , ed. Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery. Totowa, NJ: Humana Press Inc. [Google Scholar]
  8. Lysenko AV, , 1960. Use of quinocide in treatment and prophylaxis of vivax malaria. Bull World Health Organ 22: 641662. [Google Scholar]
  9. Alving AS, , 1954. Clinical treatment of malaria. Recent Adv Med Surg 2: 209218. [Google Scholar]
  10. Alving AS, Craige B, Jones R, Whorton CM, Pullman TN, Eichelberger L, , 1948. Pentaquine (Sn-13,276), a therapeutic agent effective in reducing the relapse rate in vivax malaria. J Clin Invest 27: 2533.[Crossref] [Google Scholar]
  11. Craige B, Jones R, Whorton CM, Pullman TN, Alving AS, Eichelberger L, , 1947. Clinical standardization of pamaquine (plasmochin) in mosquito-induced vivax malaria, Chesson strain. Am J Trop Med 27: 309315. [Google Scholar]
  12. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Cl Flanagan, , 1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 46: 301306. [Google Scholar]
  13. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, , 2006. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75: 402415. [Google Scholar]
  14. Earle DP, Bigelow FS, Zubrod CG, Kane CA, , 1948. Studies on the chemotherapy of the human malarias. IX. Effect of pamaquine on the blood cells of man. J Clin Invest 27: 121129.[Crossref] [Google Scholar]
  15. Atchley JA, Yount EH, , 1948. Reactions observed during treatment with pentaquine, administered with quinacrine (atabrine) metachloridine (sn-11,437) and with sulfadiazine. J Natl Malar Soc 7: 118124. [Google Scholar]
  16. Clayman CB, Arnold J, Hockwald RS, Yount EH, Edgcomb JH, Alving A, , 1952. Toxicity of primaquine in caucasians. J Am Med Assoc 149: 15631568.[Crossref] [Google Scholar]
  17. Craige B, Eichelberger L, Jones R, Alving AS, Pullman TN, Whorton CM, , 1948. The toxicity of large doses of pentaquine (sn-13,276), a new antimalarial drug. J Clin Invest 27: 1724.[Crossref] [Google Scholar]
  18. Zubrod CG, Kennedy TJ, Shannon J, , 1948. Studies on the chemotherapy of the human malarias; the physiological disposition of pamaquine. J Clin Invest 27: 114120.[Crossref] [Google Scholar]
  19. Armer RE, Barlow JS, Dutton CJ, Greenway D, Greenwood S, Lad N, Thompson AP, Thong K, Tommasini I, , 1998. 8-aminoquinolines as anticoccidials—II. Bioorg Med Chem Lett 8: 14871492.[Crossref] [Google Scholar]
  20. Bates MB, Meshnick SR, Sigler CI, Leland P, Hollingdale MR, , 1990. In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei . Am J Trop Med Hyg 42: 532537. [Google Scholar]
  21. Li XQ, Anders Bjorkman AE, Andersson TB, Gustafsson LL, Collen AE, Masimirembwa M, , 2003. Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59: 429442.[Crossref] [Google Scholar]
  22. Available at: http://www.merckmanuals.com/professional/print/lexicomp/primaquine.html.
  23. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KM, Edstein MD, , 2006. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol 61: 682689.[Crossref] [Google Scholar]
  24. Seden K, Dickinson L, Khoo S, Back D, , 2010. Grapefruit–drug interactions. Drugs 70: 23732407.[Crossref] [Google Scholar]
  25. Constantino L, Paixão P, Moreira R, Portela MJ, Do Rosario VE, Iley J, , 1999. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Exp Toxicol Pathol 51: 299303.[Crossref] [Google Scholar]
  26. Frisher H, Meillovitz RL, Ahmad T, Nora MV, , 1991. The conversion of primaquine to primaquine-aldehyde, primaquine-alcohol, and carboxyprimaquine, a major plasma metabolite. J Lab Clin Med 117: 468476. [Google Scholar]
  27. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA, , 2009. Cytochrome P450-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol 241: 1422.[Crossref] [Google Scholar]
  28. FDA, 2006. Guidance for Industry Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, MD: FDA. [Google Scholar]
  29. Available at: http://www.merckmanuals.com/professional/print/lexicomp/quinine.html. Accessed June 5, 2011.
  30. Projean D, Baune B, Farinotti R, Flinois J, Beaune P, Taburet A, Ducharme J, , 2003. In vitro metabolism of chloroquine: identification of Cyp2c8, Cyp3a4, and Cyp2d6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 31: 748754.[Crossref] [Google Scholar]
  31. Available at: http://www.merckmanuals.com/professional/print/lexicomp/chloroquine.html. Accessed June 5, 2011.
  32. Huang Y, Okochi H, May B, Legname G, Prusiner SB, Benet LZ, Guglielmo BJ, Lin ET, , 2006. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by p-glycoprotein. Drug Metab Dispos 34: 11361144.[Crossref] [Google Scholar]
  33. Karamanakos PN, Trafalis DT, Geromichalos GD, Pappas P, Harkitis P, Konstandi M, Marselos M, , 2009. Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenicity. Arch Toxicol 83: 571580.[Crossref] [Google Scholar]
  34. Edwards G, Mcgrath CS, Ward SA, Supanaranond W, Pukrittayakamee S, Davis TME, White NJ, , 1993. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol 35: 193198.[Crossref] [Google Scholar]
  35. Brewer GJ, Tarlow AR, Kellermeyer RW, Alving AS, , 1962. The hemolytic effect of primaquine. XV. Role of methemoglobin. J Lab Clin Med 59: 905916. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.11-0498
Loading
/content/journals/10.4269/ajtmh.2011.11-0498
Loading

Data & Media loading...

  • Received : 01 Aug 2011
  • Accepted : 13 Sep 2011
  • Published online : 01 Dec 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error